Floatz logo

Lanreotide

Rectal Carcinoma

University Hospital, Ghentprotein_peptidePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

33 Active assets in the Rectal Carcinoma cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 2BB
Lanreotide Autogel
University Hospital, Ghent
Phase 3B
gsk1120212
City of Hope Medical Center
Phase 2B
Binimetinib
University of California, San Francisco
Phase 2B
Palbociclib
National Cancer Institute (NCI)
Phase 2B

View all 35 →

Same molecule, other indications

Lanreotide is also rated in:

lymphoceleDormant
BB
Indicative ·
64 / 100
View asset →
malignant endocrine neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
non-functional pancreatic neuroendocrine tumorDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →